Albert Bourla (Photo by JOHN THYS/POOL/AFP via Getty Images)
April 28, 2022 12:29 PM EDTUpdated May 4, 01:05 PM
Deals
Pharma

Big Phar­ma CEOs as­sess the BD land­scape in biotech: Al­bert Bourla is stay­ing fo­cused on 2025-2030

John Carroll

Editor & Founder

One of the big ques­tions for 2022 is whether or not we’ll see move­ment on the BD front to­ward more deals and ac­qui­si­tions af­ter a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

A service from the Financial Times